Company Overview and News
Bengaluru: With low-income homes not fetching enough margins and luxury homes not finding enough takers, builders have found a sweet spot in middle-income housing projects, where buyers are willing to put up Rs25-50 lakh for a home of their own.
10:00 am Listing: Indian Energy Exchange opened sharply lower at Rs 1,500, falling 9 percent against issue of Rs 1,650 per share.
Puravankara Projects plans to build 4-4.5 million sq. ft of commercial office space over the next few years and monetize non-core land parcels to reduce debt
The board of Puravankara (formerly Puravankara Projects) on Tuesday approved an enabling resolution to exit from the investment of ₹403 crore at Raidurg, Panamaktha village.
Sun Pharma | Maruti Suzuki | Redington | Sasken Communications | Voltamp Transformers | Strides Arcolab | JK Paper | Edelweiss Financial | Tata Metaliks | Hinduja Ventures | Suzlon Energy | Mahindra & Mahindra Financial and Hinduja Ventures are stocks, which are in the news today.
The company's Q2 (August-September) net profit rose 55.9 percent at Rs 42.1 crore versus Rs 27 crore, in the same quarter last fiscal.
Puravankara Projects reported a 56.17 per cent rise in Q2 profit at ₹42.12 crore, against ₹26.97 crore in the same period last year. Revenues were 10.94 per cent lower at ₹377.53 crore (₹423.94 crore).
Puravankara Projects informed the exchange that the company's consolidated net profit (PAT) increased by 41% to Rs 42.12 crore in Q2 FY17 as compared to Rs 26.97 crore in Q2 FY16.
GOL Offshore, Electrosteel Steels, NLC India, Jindal Steel & Power, MMTC, Seamec, Puravankara Projects and SAIL will announce their Q2 and half-year results on Thursday. Besides, the board of Banco Products (I) will meet to consider a buyback proposal. Jyothy Laboratories will consider a proposal to raise funds through issuance of new non-convertible debt securities on private placement basis. Analysts will follow the developements closely.
1m - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...